Connect with us

Hi, what are you looking for?

Health Care Sector

CECMED Approves SOBERANA 02 vaccine for Children

CECMED has approved the Soberana 02 vaccine for use in the pediatric population. Photo: Atalayar

The Center for State Control of Medicines, Equipment and Medical Devices (CECMED) approved the emergency use of the SOBERANA 02 in the pediatric population aged 2 to 18 years of age. The manufacturer of the vaccine, the Finlay Vaccine Institute (IFV), had applied for approval.

CECMED approved the Soberana 02 vaccine based on the requirements of quality, safety, and immunogenicity for this group.

They based the approval on the trial results of an application of a two-dose schedule in children aged 3 to 18 years old and another in persons aged 19 to 80 years.

The results obtained in the clinical trials were superior in all variables in the group aged 19 to 80 years. It showed similar results in young adults aged 19 to 29 years.

Advertisement. Scroll to continue reading.

The safety profile showed similar results between the groups compared. They include children from age 2 in the approval, based on information provided by the IFV.

CECMED carried out inspections of the clinical testing sites where the trials took place verifying compliance with Good Clinical Practices.

Related News:

Health Care Sector

Phase III clinical trials of Cuba’s Abdala vaccine came to a close on May 1. Tests show very positive results for safety and efficacy,...

Health Care Sector

Cuba will begin the vaccination of 1.7 million residents of Havana this May according to official sources. It is part of a study in...

Health Care Sector

On Monday, Cuba began the second doses of the candidates Soberana and Abdala vaccines, in phase III of clinical trials, after setting a record...

Health Care Sector

Cuba’s successful COVID-19 response pandemic and its commitment to the health of its citizens is well known. The Lancet, founded in 1823, a respected...

error: This content is copyright protected.